{
    "nct_id": "NCT05090384",
    "official_title": "Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD",
    "inclusion_criteria": "* Newly diagnosed GVHD that meets criteria for Minnesota standard risk (see section 9.0) except isolated skin rash <25% body surface area without other manifestations.\n* Ann Arbor 1 GVHD by biomarkers\n* GVHD not previously treated systemically (topical therapies and non-absorbed steroids are allowed)\n* Any donor type, HLA-match, conditioning regimen is acceptable\n* Age 0-21 years at the time of screening\n* Signed and dated written informed consent obtained from patient or legal representative and assent from pediatric patients capable of providing assent\nHealthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Patients treated for GVHD with >0.5 mg/kg/day prednisone for any duration or any steroid treatment for GVHD for more than 2 days prior to screening.\n* Patients receiving corticosteroids >0.1 mg/kg prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD except for adrenal insufficiency, premedication for transfusions/IV medications, or intermittent use for symptom control such as nausea/vomiting\n* Relapsed, progressing, or persistent malignancy or other condition (e.g., known declining donor chimerism) requiring withdrawal of systemic immune suppression or donor leukocyte infusion (DLI)\n* Patients with uncontrolled infection (i.e., progressive symptoms related to infection despite treatment, persistently positive microbiological cultures despite treatment, viral reactivations unresponsive to treatment, or any other evidence of severe infection)\n* A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment\n* Patients who are pregnant\n* Patients requiring mechanical ventilation or cardiac pressor support",
    "miscellaneous_criteria": ""
}